Connect your AI

Celcuity CELC Convertible debentures

Convertible debentures at other companies

Cogent Biosciences, Inc.COGT

——

Other financials

Income statement

Operating income-$50.5M-39.8%

Net income-$52.8M-42.8%

EPS (diluted)-$0.97-12.8%

Balance sheet

Cash & equivalents$145.2M+781%

Total debt$137.9M+30.7%

Total equity$53.5M-38.2%

Total assets$410.2M+88.0%

Cash flow

Operating cash flow-$55.1M-53.6%

CapEx$249.0K+315%

Free cash flow-$55.3M-54.0%

Valuation

Market cap$4.28B+1,370%

Enterprise value$4.27B+1,086%

Returns & leverage

Return on equity-275.2%-990pp

Debt / equity2.6×+1.4×

Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's convertible debentures.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Celcuity's convertible debentures?: Celcuity (CELC) reported convertible debentures of $195.57M in Q1 2026.